1-5 of 5
Nicole Streiner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy

Bruno Gomes, Gregory Driessens, Derek Bartlett, Danying Cai, Sandra Cauwenberghs, Stefano Crosignani, Deepak Dalvie, Sofie Denies, Christopher P. Dillon, Valeria R. Fantin, Jie Guo, Marie-Claire Letellier, Wenlin Li, Karen Maegley, Reece Marillier, Nichol Miller, Romain Pirson, Virginie Rabolli, Chad Ray, Nicole Streiner, Vince R. Torti, Konstantinos Tsaparikos, Benoit J. Van den Eynde, Martin Wythes, Li-Chin Yao, Xianxian Zheng, Joseph Tumang, Manfred Kraus
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2018) 17 (12): 2530–2542.
https://doi.org/10.1158/1535-7163.MCT-17-1104
Published: 03 December 2018
View article titled, Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy
Open the PDF for Characterization of the Selective Indoleamine 2,3-Dioxygenase-1 (IDO1) Catalytic Inhibitor EOS200271/PF-06840003 Supports IDO1 as a Critical Resistance Mechanism to PD-(L)1 Blockade Therapy in another window
Includes: Supplementary data
Journal Articles

CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy

Adam Siddiqui-Jain, Joshua Bliesath, Diwata Macalino, Mayuko Omori, Nanni Huser, Nicole Streiner, Caroline B. Ho, Kenna Anderes, Chris Proffitt, Sean E. O'Brien, John K. C. Lim, Daniel D. Von Hoff, David M. Ryckman, William G. Rice, Denis Drygin
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2012) 11 (4): 994–1005.
https://doi.org/10.1158/1535-7163.MCT-11-0613
Published: 08 April 2012
View article titled, CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Open the PDF for CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy in another window
Includes: Supplementary data
Journal Articles

Abstract B123: Novel high content molecular characterization and anticancer drug sensitivity profiling of more clinically relevant tumor models derived from patient primary tumors.

Kesavan Praveen Nair, Nicole Streiner, Steve Hoffmaster, Martin Vo, Thomas Broudy, Cyrus Mirsaidi, Patrick O'Connor, Kenna Anderes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2011) 10 (11_Supplement): B123.
https://doi.org/10.1158/1535-7163.TARG-11-B123
Published: 12 November 2011
View article titled, Abstract B123: Novel high content molecular characterization and anticancer drug sensitivity profiling of more clinically relevant tumor models derived from patient primary tumors.
Journal Articles

Abstract C198: CX‐4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells

Denis Drygin, Josh Bliesath, Caroline Ho, Adam Siddiqui‐Jain, Sean O'Brien, Mayuko Omori, Nanni Huser, Chris Proffitt, Nicole Streiner, William G. Rice, Kenna Anderes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): C198.
https://doi.org/10.1158/1535-7163.TARG-09-C198
Published: 10 December 2009
View article titled, Abstract C198: CX‐4945, a novel small molecule inhibitor of CK2 protein kinase, reduces hyperactivated Akt signaling and synergizes with Akt inhibitors in breast cancer cells
Journal Articles

Abstract A246: Discovery of selective small molecule Pan‐Pim kinase inhibitors with potent oral efficacy in murine xenograft models

Sean O'Brien, Mustapha Haddach, Cosmin Borsan, Jerome Michaux, Pauline Kerdoncuff, Michael Schwaebe, Fabrice Pierre, Eric Stefan, Anne‐Sophie Nedellec, Adam Siddiqui‐Jain, Nicole Streiner, Diwata Macalino, Denis Drygin, Caroline Ho, Josh Bliesath, May Omori, Ryan Stansfield, Jennifer Phung, David Ryckman, William Rice, Kenna Anderes
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A246.
https://doi.org/10.1158/1535-7163.TARG-09-A246
Published: 10 December 2009
View article titled, Abstract A246: Discovery of selective small molecule Pan‐Pim kinase inhibitors with potent oral efficacy in murine xenograft models